REGN:NSD-Regeneron Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 533.89

Change

+15.96 (+3.08)%

Market Cap

USD 55.27B

Volume

1.00M

Average Target Price

USD 642.05 (+20.26%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.36 (+2.82%)

USD58.65B 22.10 18.26
MRNA Moderna, Inc

-4.64 (-3.58%)

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+2.01 (+1.28%)

USD34.27B 36.37 33.83
SGEN Seagen Inc

+3.03 (+1.63%)

USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

-0.10 (-0.19%)

USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

+11.68 (+3.39%)

USD31.01B N/A N/A
GMAB Genmab A/S

-0.07 (-0.16%)

USD28.77B 26.59 3.08
BNTX BioNTech SE

+3.11 (+3.06%)

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
INCY Incyte Corporation

+3.40 (+3.75%)

USD19.83B 47.64 35.20

ETFs Containing REGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+3.27 (+1.81%)

USD0.48B
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.08 (+0.71%)

USD0.02B
HERS-B:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.10 (+1.39%)

USD0.27B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.06 (+1.05%)

USD0.19B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.10 (+1.36%)

USD0.27B
MINV:LSE iShares Edge MSCI World M.. 0.00 % 0.30 %

-3.50 (-0.09%)

N/A
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

+6.00 (+0.12%)

N/A
XDEB:LSE Xtrackers MSCI World Mini.. 0.00 % 0.25 %

-1.00 (-0.04%)

USD0.66B
HWF:CA Middlefield Health & Well.. 0.00 % 0.85 %

+0.23 (+1.83%)

USD0.05B
IQQ0:F iShares Edge MSCI World M.. 0.00 % 0.30 %

+0.02 (+0.03%)

N/A
SXR0:F iShares Edge MSCI World M.. 0.00 % 0.35 %

+0.02 (+0.39%)

N/A
XDEB:F Xtrackers MSCI World Mini.. 0.00 % 0.25 %

+0.05 (+0.15%)

USD0.53B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+0.81%)

N/A
FTGU:XETRA First Trust US Large Cap .. 0.00 % 0.00 %

-0.12 (-0.24%)

N/A
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.30 %

-0.06 (-0.13%)

N/A
SXR0:XETRA iShares Edge MSCI World M.. 0.00 % 0.35 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.21 (+2.36%)

USD0.24B
LS:CA Middlefield Healthcare &a.. 0.00 % 0.85 %

-0.20 (-1.69%)

USD0.08B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+4.02 (+4.11%)

USD0.24B
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.35 %

N/A

USD0.26B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.80 (-3.89%)

USD9.34M
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+3.10 (+1.76%)

USD2.04B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

+0.32 (+0.83%)

USD0.02B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

+3.12 (+1.93%)

USD10.37B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

-0.99 (-5.02%)

USD0.16B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

+0.23 (+0.80%)

USD0.05B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+1.34 (+1.75%)

USD0.26B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
DWPP First Trust Dorsey Wright.. 0.00 % 0.60 %

+0.22 (+0.78%)

USD0.01B
XMS:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

-0.04 (-0.14%)

USD0.05B
XMU:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

+0.08 (+0.14%)

USD0.44B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

+0.13 (+0.30%)

USD0.24B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

-0.07 (-0.27%)

USD0.06B
XT iShares Exponential Techn.. 0.00 % 0.47 %

+1.00 (+1.69%)

USD3.11B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
HERS:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

USD3.37M
ENTR ERShares Entrepreneur 30 .. 0.00 % 0.49 %

+0.68 (+2.42%)

USD0.15B
XDEB:XETRA Xtrackers MSCI World Mini.. 0.00 % 0.25 %

-0.07 (-0.23%)

USD0.66B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.51% 44% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.51% 44% F 64% D
Trailing 12 Months  
Capital Gain 46.79% 64% D 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.79% 64% D 73% C
Trailing 5 Years  
Capital Gain 15.67% 53% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.67% 53% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 13.57% 56% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.57% 56% F 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 38.25% 68% D+ 36% F
Risk Adjusted Return 35.48% 65% D 60% D-
Market Capitalization 55.27B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.98 34% F 51% F
Price/Book Ratio 5.46 45% F 30% F
Price / Cash Flow Ratio 22.74 5% F 18% F
EV/EBITDA 14.64 25% F 56% F
Management Effectiveness  
Return on Equity 30.60% 98% A+ 96% A
Return on Invested Capital 19.11% 93% A 91% A-
Return on Assets 12.99% 98% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.38 56% F 54% F
Short Percent 2.91% 76% C 53% F
Beta 0.30 93% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.